4-Methyl-DMT, or 4-Me-DMT, also known as 4-methyl-N,N-dimethyltryptamine or as 4,N,N-trimethyltryptamine (4,N,N-TMT or 4-TMT), is a serotonin receptor modulator and possible psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT) and psilocin (4-HO-DMT).
4-Methyl-DMT was not included nor mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved). Its dose in humans is unknown.
The related drug 4-methyl-AMT has shown mixed findings in terms of hallucinogenic effects in humans and is clearly less potent than ñ-methyltryptamine (AMT) in such regards.
4-Methyl-DMT showed affinity for the serotonin receptors in the isolated rat stomach fundus strip (A<sub>2</sub> = 141nM). Its affinity for these receptors was 7-fold higher than that of dimethyltryptamine (DMT), roughly the same as that of psilocin (4-HO-DMT), and about 60% of that of 5-MeO-DMT. However, this assay was subsequently found to be an unreliable predictor of hallucinogenic activity. The receptor in this tissue may correspond to the serotonin 5-HT<sub>2B</sub> receptor.
In other studies, 4-methyl-DMT was assessed and showed affinity for the serotonin 5-HT<sub>1E</sub> receptor (K<sub>i</sub> = 470nM) and for the serotonin 5-HT<sub>1F</sub> receptor (K<sub>i</sub> = 198nM). These affinities were similar to but slightly lower than those of DMT (K<sub>i</sub> = 300nM and 130nM, respectively).
Like DMT and 5-MeO-DMT, 4-methyl-DMT fully substituted for the psychedelic drug DOM in rodent drug discrimination tests. It was a little more than twice as potent as DMT in this assay but was about half as potent as 5-MeO-DMT. Similarly to diethyltryptamine (DET) and dipropyltryptamine (DPT), 4-methyl-DMT produced behavioral disruption at higher doses.
The chemical synthesis of 4-methyl-DMT has been described.
Analogues of 4-methyl-DMT include dimethyltryptamine (DMT), psilocin (4-HO-DMT), 4-fluoro-DMT, 4-MeO-DMT, 4-MeO-DET, 1-methyl-DMT, 2-methyl-DMT, 4-methyl-AMT, 4-methyl-AET, 5-methyl-DMT, 6-methyl-DMT, 7-methyl-DMT, and RS134-49 (4-methyl-THPI), among others.
4-Methyl-DMT was first described in the scientific literature by Richard Glennon and colleagues by 1983.
4-Methyl-DMT is not an explicitly nor implicitly controlled substance in Canada as of 2025.
4-Methyl-DMT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.